CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company’s commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcar...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
CareDx, Inc. Announces the Launch of Olerup QTYPE®
Sep 28 16
CareDx Inc. announced the launch of Olerup QTYPE® at the 42nd Annual Meeting of the American Society of Histocompatability and Immunogenetics (ASHI) in St. Louis, MO. Olerup QTYPE is a robust and easy to use alternative for rapid HLA typing within one hour. This new test brings several needed features to HLA labs, including speed and precision. Olerup QTYPE is currently for use on the Roche LightCycler 480II, a robust and well established RT-PCR instrument. Validation studies are also underway for the use of Olerup QTYPE on the ABI suite of instruments. Multiple product demonstrations have been scheduled at several HLA laboratories across the US and Europe.
CareDx, Inc announced delayed 10-Q filing
Aug 16 16
On 08/16/2016, CareDx, Inc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Caredx, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year 2016
Aug 10 16
CareDx Inc. reported Unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported total revenue of $10,708,000 against $7,129,000 a year ago. Loss from operations was $6,849,000 against $2,886,000 a year ago. Loss before income taxes was $10,728,000 against $3,185,000 a year ago. Net loss attributable to the company was $10,335 against $3,185,000 a year ago. Net loss per basic and diluted share attributable to the company was $0.76 against $0.27 a year ago. Non-GAAP net loss was $3,945,000 against $2,632,000 a year ago. Non-GAAP basic and diluted net loss per share attributable the company was $0.29 against $0.22 a year ago. The increase in the year-over-year net loss reflects acquisition costs, acquisition related amortization of intangible assets, purchase accounting adjustments, a charge for a change in the estimated fair value of warrants, and investment in the development of AlloSure. The increase in the year-over-year non-GAAP net loss primarily reflects its investment in the development of AlloSure.
For the six months, the company reported total revenue of $17,270,000 against $14,344,000 a year ago. Loss from operations was $13,418,000 against $4,277,000 a year ago. Loss before income taxes was $20,433,000 against $5,457,000 a year ago. Net loss attributable to the company was $20,087,000 against $5,457,000 a year ago. Net loss per basic and diluted share attributable to the company was $1.57 against $0.46 a year ago. Non-GAAP net loss was $8,326,000 against $4,876,000 a year ago. Non-GAAP basic and diluted net loss per share attributable the company was $0.64 against $0.41 a year ago.
For the full year 2016, the company reiterates revenue guidance. The company expects fiscal 2016 revenue to grow by low- to mid-single digits on a pro forma basis over fiscal 2015 revenue, assuming that the Allenex acquisition closed on January 1, 2016. Actual reported results will only include Allenex results subsequent to the close of the acquisition on April 14, 2016, and the company expects reported revenue for the full year 2016 to be in the range of $40 million to $42 million.